Actively Recruiting
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-09
200
Participants Needed
4
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying multiple myeloma (MM), a complex blood cancer, to improve how well doctors can predict which patients might experience early disease return after treatment. This research uses advanced machine learning methods to analyze clinical, genomic, and imaging information from MM patients, aiming to develop models that better forecast treatment response and risk of early relapse. The study is observational and conducted across multiple centers with a focus on improving personalized care for MM patients. The study collects and processes a wide range of data from patients with active multiple myeloma, including clinical details, tumor characteristics, and immune markers. Machine learning tools will combine this data to identify patient groups with similar disease features related to early progression. There are no experimental treatments given, as this is a non-interventional study that observes and analyzes existing patient data to enhance risk prediction models. Participants aged 18 years or older with a diagnosis of active multiple myeloma who agree to join the study will have their clinical and biological data collected and analyzed. The main outcome measured is the overall response rate to therapy within 12 months from the start of treatment. This study aims to generate new insights to support personalized treatment decisions and better management of MM. The study starts in October 2024 and will continue until August 2026, with no additional treatments or procedures beyond regular care and data collection.
CONDITIONS
Brief Title
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 218 years
- Signed Informed Consent form for study participation and personal data processing
- Diagnosis of active multiple myeloma
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants who undergo routine care are observed to collect clinical, genomic, and imaging data for integration into machine learning models aimed at improving risk prediction of early disease progression.
Data collection aligned with routine healthcare visits
Trial Site Locations
Total: 4 locations
1
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
Meldola, Forlì-Cesena, Italy, 47014
Not Yet Recruiting
2
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
3
ARNAS "G. Brotzu" di Cagliari
Cagliari, Italy, 09134
Not Yet Recruiting
4
Azienda Ospedaliera Universitaria Federico II
Naples, Italy, 80131
Not Yet Recruiting
Research Team
E
Elena Zamagni, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here